Immunotherapy in Lung Cancer | Specialty

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Nivolumab Plus Chemotherapy Moves Into Neoadjuvant Setting in NSCLC

May 4th 2022

Mark Awad, MD, PhD, discusses how the approval of nivolumab opens the door for the new regimen to become a backbone for future treatment strategies.

Treatment Decisions in Non–Small Cell Lung Cancer

April 6th 2022

This publication highlights insights from expert stakeholders on the evolving therapeutic landscape of immunotherapy-based treatment regimens through a review of clinical scenarios of patients with non-small cell lung cancer.

Tiragolumab Plus Atezolizumab/Chemo Misses PFS End Point in Extensive-Stage SCLC

March 30th 2022

The addition of the anti-TIGIT immunotherapy tiragolumab to atezolizumab plus carboplatin/etoposide failed to significantly improve progression-free survival over atezolizumab/chemotherapy alone when used in the frontline treatment of patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase 3 SKYSCRAPER-02 trial.

Adjuvant Pembrolizumab Improves DFS in Stage IB to IIIA NSCLC, Irrespective of PD-L1 Expression

March 18th 2022

Pembrolizumab was found to significantly improve disease-free survival vs placebo when used in the adjuvant treatment of patients with stage IB to IIIA non–small cell lung cancer following surgical resection, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

FDA Approves Neoadjuvant Nivolumab/Chemo for Resectable NSCLC

March 4th 2022

The FDA has approved nivolumab plus platinum-doublet chemotherapy for adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer

February 8th 2022

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC

February 7th 2022

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC

February 7th 2022

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

Immunotherapy Advances Drive Progress in Lung Cancer Treatment

February 5th 2022

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC

February 5th 2022

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

Sugemalimab Plus Chemo Significantly Improves Survival in Frontline Stage IV NSCLC

January 19th 2022

The addition of the PD-L1 inhibitor sugemalimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in the frontline treatment of patients with stage IV non–small cell lung cancer.

Adjuvant Pembrolizumab Improves DFS in Stage IB-IIIA NSCLC, Irrespective of PD-L1 Expression

January 10th 2022

Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

Tiragolumab Plus Atezolizumab Demonstrates Improvement in PFS, OS, ORR in PD-L1+ NSCLC

January 4th 2022

The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.

FDA Grants Fast Track Status to Novel Gene Therapy Plus Pembrolizumab for Late-Stage NSCLC

January 3rd 2022

The FDA has granted a fast track designation to a combination comprised of the immunogene therapy quaratusugene ozeplasmia and pembrolizumab for use in select patients with late-stage non–small cell lung cancer.

Immune Checkpoint Inhibitors Extend Survival for Mesothelioma

December 28th 2021

Immune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.

Second-Line Treatment of SCLC

December 22nd 2021

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Updated Results of the CASPIAN Trial in SCLC From ESMO 2021

December 22nd 2021

John V. Heymach, MD, PhD, reviews updated results from the phase III CASPIAN trial for patients with extensive-stage SCLC (small cell lung cancer) as presented at ESMO 2021.

Immunotherapies in the Treatment of Extensive-Stage SCLC

December 22nd 2021

Sandip P. Patel, MD, reviews results and clinical implications from the CASPIAN study, and Heather Wakelee, MD, shares insight on approaching the optimal immunotherapy option for patients with extensive-stage SCLC.

Real-World Data Underscores Efficacy of Durvalumab in NSCLC

December 17th 2021

Real-world data from the PACIFIC-R trial evaluating durvalumab following chemoradiotherapy in patients with stage III, unresectable non–small cell lung cancer provide evidence supporting the agent’s efficacy in this population, solidifying its role as a standard-of-care treatment

IMpower133 Trial for Extensive-Stage SCLC

December 17th 2021

Stephen Liu, MD, reviews outcomes from the IMpower133 trial and comments on the current standard of care for the first-line treatment of extensive-stage SCLC.